Ellen Schaaf v. SmithKline Beecham Corporation

602 F. Supp. 3d 1236, 602 F.3d 1236, 15 Wage & Hour Cas.2d (BNA) 1857, 76 Fed. R. Serv. 3d 799, 2010 U.S. App. LEXIS 7074, 93 Empl. Prac. Dec. (CCH) 43,856, 2010 WL 1286781
Court of Appeals for the Eleventh Circuit·Decided April 6, 2010·No. 09-10806·Published·Cited by 77 cases

Opinion

BLACK, Circuit Judge:

Appellant Ellen Schaaf worked for GlaxoSmithKline as a Regional Vice President, but, after returning from maternity leave, was demoted to District Sales Manager. Schaaf then sued GSK, alleging that her maternity leave impermissibly contributed to her demotion. The district court granted summary judgment on some of her claims and judgment as a matter of law on others, all in favor of GSK. Schaaf appeals these orders; this Court affirms the district court.

I. BACKGROUND

Schaaf worked for GlaxoSmithKline (GSK) first as a Sales Representative and then as a District Sales Manager (DSM) before assuming the role of Regional Vice President (RVP) in 1999. In her new role as RVP, Schaaf was tasked with overseeing a region that included all of Florida and a portion of southern Georgia — a region that, at the time, had consistently failed to meet GSK’s sales expectations. Schaaf s superiors encouraged her to address these shortfalls by approaching the RVP position with creativity and innovation, and indicated that the goal of increasing sales volume in the faltering region was of central importance. After a few years at the helm, the early signs indicated that Schaaf had successfully risen to the challenge; under her direction, the region’s performance increased markedly *1239 and its sales figures returned to satisfactory levels.

Although initial indications seemed positive, problems between Schaaf and her subordinates eventually tainted Schaafs managerial accomplishments. In July 2002, three DSMs working under Schaaf— Liz Murray, Stewart Miller, and Jose Castrillo — lodged complaints with the GSK Human Resources (HR) department, bemoaning Schaafs alleged unprofessional management style. HR then interviewed each of these three DSMs, in addition to all of the other GSK employees who reported directly to Schaaf. The other employees verified Murray, Miller, and Castrillo’s initial complaints regarding Schaafs management, and, in some cases, further elaborated on her alleged faults.

The interviews revealed both broad complaints and specific grievances about Schaaf. For example, the employees complained about Schaafs antagonistic and inflexible management style, chronic inaccessibility, poor communication skills, harsh and demanding demeanor, and tendency to play favorites, as well as about her failure to provide written feedback on performance appraisals, her practice of sharing some DSMs’ confidential performance-evaluation information with other employees, her unwillingness to respond to voice-mail messages for weeks at a time, and her failure to acknowledge the contributions of her subordinates. The interviews left no question as to how the DSMs viewed Schaaf as a supervisor. For instance, one employee lamented the “[t]errible” state of the region’s morale, explaining, “Morale can’t be positive. Just no way. You don’t know when she is going to strike. Only thing predictable is that it’s going to be nasty.... ” Another reported that Schaaf was simply “not open to hearing differing viewpoints,” and a third starkly described Schaaf as “very cold and uncaring.” Schaafs subordinates reiterated that Schaafs management defects contributed significantly to the group’s low morale.

After these initial interviews with the subordinates, GSK also interviewed Schaaf to offer her a chance to respond to their concerns. GSK then determined that the employees’ grievances were severe and pervasive enough to warrant taking formal disciplinary action against Schaaf by issuing her a Verbal Warning. Lisa Gonzalez, Schaafs immediate superior, also instructed Schaaf to complete a so-called Performance Improvement Plan (PIP) with the goal of bettering her communication skills and management style. According to GSK, the improvement plan was designed to allow Schaaf an opportunity to correct her shortcomings and to foster improved relationships with her subordinates — for instance, the PIP required Schaaf to issue previously uncompleted written performance reviews to her subordinates, to attend management-training programs, and to complete team-building exercises with her subordinates.

Incidentally, in July 2002, the same month that Murray, Miller, and Castrillo first complained to HR, Schaaf informed Gonzalez, her superior, that Schaaf was pregnant with her fourth child and planned to take maternity leave beginning in early 2003. 1 As a result, Schaaf expressed some concern regarding her ability to complete the PIP prior to the commencement of her leave. Rather than making a diligent attempt to satisfy the plan’s requirements and to demonstrate her willingness to improve herself professionally, however, Schaaf instead ignored several PIP deadlines, including deadlines to register for *1240 the required management courses and to complete the written performance evaluations. Schaaf even failed to meet the deadline for simply returning a signed copy of the plan to her superiors. As a result of this demonstrated unwillingness to cooperate, Schaaf did not satisfy the PIP’s requirements by the target date of December 5, 2002. Gonzalez then extended this time frame until mid-January 2003, and, when Schaaf likewise failed to meet this new deadline, Gonzalez extended it again until after Schaaf returned from her maternity leave.

Schaaf began her leave on January 21, 2003. During her absence, an interim RVP took her place, and the subordinates reported that the region functioned significantly better while Schaaf was gone. While serving as RVP, the interim also discovered and corrected several significant administrative problems that had occurred under Schaafs watch, including scores of expense reports that Schaaf had ignored and several invoices from outside creditors that Schaaf had failed to pay. The subordinates reported that, under the interim RVP, productivity had increased, communication had improved, and morale was markedly higher.

Shortly before Schaafs return, the DSMs requested a meeting with Gonzalez, Schaafs superior, to express their concerns that the region’s increased morale and productivity could dissipate immediately if Schaaf resumed her role as RVP. Gonzalez took these reservations seriously: when Schaaf returned to work on April 15, 2003, she was immediately instructed to travel to Gonzalez’s office in North Carolina. Once there, Gonzalez gave Schaaf a choice: she could either accept a demotion to District Sales Manager or leave the company, but in any case she would not be reinstalled as RVP. Schaaf eventually accepted the demotion to DSM, and submitted a request for a written statement of the reasons for her demotion.

GSK provided the requested written response, in which it informed Schaaf that her subordinates had complained of her overbearing and hostile management style and that her region functioned markedly better in her absence. GSK also indicated that Schaafs failure to complete the PIP requirements and her demonstrated unwillingness to change her management behavior contributed to her demotion. Schaaf then sued, claiming that GSK impermissibly demoted her for reasons related to her statutorily protected maternity leave.

II. DISCUSSION

Schaaf raises a number of issues on appeal, but her primary arguments center on whether GSK violated Schaafs rights under the Family and Medical Leave Act (FMLA).

Free access — add to your briefcase to read the full text and ask questions with AI

Ellen Schaaf v. SmithKline Beecham Corporation, 602 F. Supp. 3d 1236, 602 F.3d 1236, 15 Wage & Hour Cas.2d (BNA) 1857, 76 Fed. R. Serv. 3d 799, 2010 U.S. App. LEXIS 7074, 93 Empl. Prac. Dec. (CCH) 43,856, 2010 WL 1286781 (11th Cir. 2010).

602 F. Supp. 3d 1236 (Ellen Schaaf v. SmithKline Beecham Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related